SLCO2B1 and Myalgia: One study evaluated the antitumor activity of a combination of erlotinib with the OATP2B1 substrate rosuvastatin32 in 24 patients with advanced solid malignancies.33 In this study, muscle toxicity was observed at a substantially higher rate (34%) than during standard statin therapy (1–5%), with seven cases of myalgia and one case of rhabdomyolysis resulting in a study‐related death.